论文部分内容阅读
目的:探讨非小细胞肺癌(NSCLC)EGFR突变与ERCC1、BRCA1表达的相关性。方法:收集符合入组条件的NSCLC患者151例,应用RT-PCR方法检测EGFR突变,采用免疫组化DAB法检测ERCC1、BRCA1蛋白表达,应用Fisher精确检验对EGFR突变状态与ERCC1、BRCA1的表达进行相关性分析。结果:151例患者中,EGFR突变37例,ERCC1低、中、高表达率分别为43.2%(16/37)、54.1%(20/37)和2.7%(1/37),EGFR突变与ERCC1表达有相关性,P=0.009;BRCA1低、中、高表达率分别为43.2%(16/37)、48.6%(18/37)和8.1%(3/37),EGFR突变与BRCA1表达无相关性,P=0.323。结论:NSCLC EGFR突变与ERCC1蛋白表达有相关性,与BRCA1蛋白表达无相关性。
Objective: To investigate the relationship between EGFR mutation and expression of ERCC1 and BRCA1 in non-small cell lung cancer (NSCLC). Methods: 151 NSCLC patients were enrolled and EGFR mutation was detected by RT-PCR. The expression of ERCC1 and BRCA1 protein was detected by immunohistochemical DAB method. The mutation status of EGFR and the expression of ERCC1 and BRCA1 were analyzed by Fisher’s exact test Correlation analysis. Results: Of the 151 patients, EGFR mutations were found in 37 cases. The low, middle and high expression rates of ERCC1 were 43.2% (16/37), 54.1% (20/37) and 2.7% (1/37), respectively. (P = 0.009). The low, middle and high expression rates of BRCA1 were 43.2% (16/37), 48.6% (18/37) and 8.1% (3/37) respectively. There was no correlation between EGFR mutation and BRCA1 expression Sex, P = 0.323. Conclusion: There is a correlation between EGFR mutation and ERCC1 protein expression in NSCLC and no correlation with BRCA1 protein expression.